Below are the most recent publications written about "Lithium" by people in Profiles.
-
Schmidt CT, Deligiannidis KM, Kittel-Schneider S, Frodl T, Spigset O, Paulzen M, Schoretsanitis G. Transfer of anticonvulsants and lithium into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023 06 08; 124:110733.
-
Moradi F, Eslami F, Rahimi N, Koohfar A, Shayan M, Maadani M, Ghasemi M, Dehpour AR. Modafinil exerts anticonvulsive effects against lithium-pilocarpine-induced status epilepticus in rats: A role for tumor necrosis factor-a and nitric oxide signaling. Epilepsy Behav. 2022 05; 130:108649.
-
Sheibani M, Ghasemi M, Dehpour AR. Lithium and Erectile Dysfunction: An Overview. Cells. 2022 01 05; 11(1).
-
Katz IR, Rogers MP, Lew R, Thwin SS, Doros G, Ahearn E, Ostacher MJ, DeLisi LE, Smith EG, Ringer RJ, Ferguson R, Hoffman B, Kaufman JS, Paik JM, Conrad CH, Holmberg EF, Boney TY, Huang GD, Liang MH. Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022 01 01; 79(1):24-32.
-
Smith EG, Austin KL, Kim HM, Miller DR, Sauer BC, Valenstein M. Suicide death over the first year of lithium versus valproate treatment in cohorts with and without bipolar disorder. J Psychiatr Res. 2022 03; 147:349-356.
-
Eslami F, Rahimi N, Ostovaneh A, Ghasemi M, Dejban P, Abbasi A, Dehpour AR. Sumatriptan reduces severity of status epilepticus induced by lithium-pilocarpine through nitrergic transmission and 5-HT1B/D receptors in rats: A pharmacological-based evidence. Fundam Clin Pharmacol. 2021 Feb; 35(1):131-140.
-
Tobe BTD, Crain AM, Winquist AM, Calabrese B, Makihara H, Zhao WN, Lalonde J, Nakamura H, Konopaske G, Sidor M, Pernia CD, Yamashita N, Wada M, Inoue Y, Nakamura F, Sheridan SD, Logan RW, Brandel M, Wu D, Hunsberger J, Dorsett L, Duerr C, Basa RCB, McCarthy MJ, Udeshi ND, Mertins P, Carr SA, Rouleau GA, Mastrangelo L, Li J, Gutierrez GJ, Brill LM, Venizelos N, Chen G, Nye JS, Manji H, Price JH, McClung CA, Akiskal HS, Alda M, Chuang DM, Coyle JT, Liu Y, Teng YD, Ohshima T, Mikoshiba K, Sidman RL, Halpain S, Haggarty SJ, Goshima Y, Snyder EY. Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proc Natl Acad Sci U S A. 2017 05 30; 114(22):E4462-E4471.
-
Smith EG, Austin KL, Kim HM, Eisen SV, Kilbourne AM, Miller DR, Zivin K, Hannemann C, Sauer BC, Valenstein M. Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders. Br J Psychiatry. 2015 Jul; 207(1):55-63.
-
Smith EG. Additional effect size measures helpful in understanding lithium and valproate trial results. Am J Psychiatry. 2012 Jan; 169(1):97-8; author reply 99.
-
Ghasemi M, Dehpour AR. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci. 2011 Jul; 32(7):420-34.